News | Heart Valve Technology | October 06, 2016

Two-Year Xeltis Bioabsorbable Valve Data Shows Positive Functionality

Feasibility clinical trial of five patients showed potential to reduce implant-related complications following surgery

Xeltis bioabsorbable valve implant, two-year data, EACTS 2016

October 6, 2016 — Xeltis announced this week that patients implanted with its bioabsorbable cardiovascular conduit showed positive functionality results two years after surgery. The data have been presented at the 30th European Association for Cardio-Thoracic Surgery (EACTS) annual scientific meeting, Oct. 1-5 in Barcelona, Spain.

“The two-year data for the Xeltis devices are very impressive,” said Thierry Carrel, M.D., professor of surgery at the Clinic for Cardiovascular Surgery, University Hospital Bern (Switzerland). “Ultrasound and MRI [magnetic resonance imaging] examinations have demonstrated anatomical and functional stability in all patients after two years, when Xeltis’ implant will have been gradually absorbed in the body and functionality replaced by components of native tissue formed within and around the implant.”

Xeltis’ feasibility clinical trial was conducted in five patients, aged 4 to 12 years at time of surgery, with only one functioning ventricle. According to the study conclusion, Xeltis’ bioabsorbable technology has the potential to improve cardiac and vascular surgical procedures by reducing implant-related complications.

In another session at EACTS, Gerardus Bennink, M.D., head and chief Pediatric Cardio-Thoracic Congenital Surgery, Heart Center of the University of Cologne (Germany) presented positive one-year in vivo preclinical data of Xeltis’ bioabsorbable pulmonary heart valve. The study results confirmed the safety and functionality of Xeltis’ valve.

Endogenous Tissue Restoration (ETR) is a novel therapeutic approach in cardiovascular regenerative medicine enabling the restoration within the body of complex cardiac parts with patient’s own tissue. The porous structure of a Xeltis’ bioabsorbable heart valve enables cardiovascular restoration by harnessing the body’s natural healing process to pervade it with new healthy tissue once implanted. As a new healthy heart valve or blood vessel made of patient’s own tissue forms around the structure of the implant and takes over functionality, the implanted valve gets absorbed in the body.

Watch a video exp[laining how the Xeltis technology works.

The combination of the successful clinical study on Xeltis technology and the positive outcomes of the preclinical study of Xeltis’ pulmonary valve paved the way for the company to commence its current Xplore-I clinical study on a bioabsorbable pulmonary heart valve. Xplore-I is a multisite feasibility trial currently enrolling pediatric patients in leading heart centers in Europe. Xeltis announced at the EACTS annual meeting that three pediatric patients have already been successfully implanted as part of the trial.

For more information: www.xeltis.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...